Literature DB >> 31473209

Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy.

Qijie Zhang1, Jiadong Xia1, Yi Wang2, Jiayi Zhang1, Chengjian Ji1, Rong Cong1, Yamin Wang3, Ninghong Song4.   

Abstract

Given the critical role of the tumor microenvironment in PCa progression, we aimed to assess the prognostic effect of tumor infiltrating M2 macrophages (TIMMs) on biochemical recurrence (BCR) in patients with localized prostate cancer (PCa) after radical prostatectomy. A total of 127 localized PCa patients from GSE116918, 268 patients from TCGA database and 77 patients from GSE70770 were enrolled in our study. TIMMs were evaluated by the CIBERSORT method. Patients with high TIMMs had a significantly poorer recurrence free survival (RFS) (P = 0.017, P = 0.0063 and P = 0.001) in the three sets. In the multivariate analysis, the presence of high TIMMs (HR = 3.026, P = 0.023; HR = 2.679, P = 0.017; HR = 2.648, P = 0.005) was identified as an independent prognostic factor for RFS in the three sets. Harrell's Concordance index (C-index) increased in all three sets after combining TIMMs with traditional risk factors (PSA, clinical stage(T) and Gleason score). Gene Set Enrichment Analysis showed that T cell receptor signaling pathway, B cell receptor signaling pathway and primary immunodeficiency were significantly enriched in the low TIMMs group. TIMMs could serve as an independent prognostic factor for BCR in localized PCa patients after RP. Incorporation of TIMMs into traditional risk classification might further stratify patients with different prognosis.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biochemical recurrence; CIBERSORT; Localized prostate cancer; M2 macrophages; Prognosis

Year:  2019        PMID: 31473209     DOI: 10.1016/j.yexcr.2019.111588

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer.

Authors:  Yichi Zhang; Yifeng Lin; Daojun Lv; Xiangkun Wu; Wenjie Li; Xueqing Wang; Dongmei Jiang
Journal:  PeerJ       Date:  2022-01-25       Impact factor: 2.984

2.  Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis.

Authors:  Xiaoying Wan; Boxiong Xie; Hui Sun; Weiqing Gu; Chunyan Wang; Qinfang Deng; Songwen Zhou
Journal:  Cancer Cell Int       Date:  2022-02-15       Impact factor: 5.722

3.  CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling.

Authors:  Tao Xie; Du-Jiang Fu; Zhi-Min Li; Dao-Jun Lv; Xian-Lu Song; Yu-Zhong Yu; Chong Wang; Kang-Jin Li; Baoqian Zhai; Jiacheng Wu; Ning-Han Feng; Shan-Chao Zhao
Journal:  Mol Cancer       Date:  2022-09-01       Impact factor: 41.444

4.  Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer.

Authors:  Erika Heninger; Nan Sethakorn; David Kosoff; Peiman Hematti; Morgan D Kuczler; Kenneth J Pienta; Joshua M Lang
Journal:  Oncotarget       Date:  2020-11-17

5.  Development and Validation of Novel Biomarkers Related to M2 Macrophages Infiltration by Weighted Gene Co-Expression Network Analysis in Prostate Cancer.

Authors:  Ning Xu; Ru-Nan Dong; Ting-Ting Lin; Tian Lin; Yun-Zhi Lin; Shao-Hao Chen; Jun-Ming Zhu; Zhi-Bin Ke; Fei Huang; Ye-Hui Chen; Xue-Yi Xue
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

6.  Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs.

Authors:  Clovis Boibessot; France-Hélène Joncas; Aerin Park; Zohra Berrehail; Jean-François Pelletier; Typhaine Gris; Alain Bergeron; Paul Toren
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.